ArticleBreast cancer research and treatment2018

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Lynne I Wagner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.